Association between SIRT1 gene polymorphisms and susceptibility to coronary artery disease: a systematic review and meta-analysis
Frontiers in Cardiovascular Medicine · 03.07.2026 · 13
DOI: 10.3389/fcvm.2026.1850297 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 03.07.2026. Verfasst von Di An und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory of Myocardial Remodeling Research, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This systematic review and meta-analysis aimed to evaluate and quantitatively synthesize the available evidence on the association between SIRT1 gene polymorphisms and susceptibility to coronary artery disease (CAD).
Methods
PubMed, Embase, Web of Science, and the Cochrane Library were systematically searched from inception to February 12, 2026, to identify relevant observational studies. Literature screening, data extraction, and quality assessment were independently performed by two reviewers. Meta-analyses were conducted using Stata 16.0, with odds ratios (ORs) and 95% confidence intervals (CIs) as effect measures. Subgroup and sensitivity analyses were further performed where appropriate.
Results
A total of nine studies were included, with overall methodological quality ranging from moderate to high. Three SIRT1 polymorphisms, rs7069102, rs7895833, and rs4746720, were included in the quantitative synthesis. In the overall analysis, rs7069102 was not significantly associated with CAD susceptibility under any of the five genetic models; however, in the CAD subgroup, it showed a consistent risk effect across all genetic models. Rs7895833 was associated with increased CAD susceptibility only under the recessive model (OR = 1.49, 95% CI: 1.03–2.15). Rs4746720 showed significant associations under the dominant model (OR = 1.26, 95% CI: 1.02–1.55) and the heterozygote model (OR = 1.27, 95% CI: 1.01–1.58).
Conclusion
Current evidence suggests that certain SIRT1 polymorphisms may be associated with CAD susceptibility, but the observed associations appear to vary by SNP locus, genetic model, and population or disease subgroup. Because the pooled estimates were derived mainly from unadjusted genotype frequencies and could not account for major cardiovascular risk factors, these findings should be interpreted cautiously. Further large, well-designed studies with appropriate adjustment for clinical confounders are needed to confirm these associations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Key Laboratory of Myocardial Remodeling Research, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
- Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
- The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
Zitieren
APA
An, D., Wu, H., Wu, S., Deng, Y., Yang, S., Wang, W., Xiang, Y., & Liu, X. (2026). Association between SIRT1 gene polymorphisms and susceptibility to coronary artery disease: a systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1850297
Vancouver
An D, Wu H, Wu S, Deng Y, Yang S, Wang W, et al. Association between SIRT1 gene polymorphisms and susceptibility to coronary artery disease: a systematic review and meta-analysis. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1850297
BibTeX
@article{An2026,
author = {An, Di and Wu, Huan and Wu, Shujin and Deng, Yuanpeng and Yang, Shuangshuang and Wang, Wansheng and Xiang, Yi and Liu, Xingde},
title = {Association between SIRT1 gene polymorphisms and susceptibility to coronary artery disease: a systematic review and meta-analysis},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1850297}
}
EUVIMED